The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
 
Yoshitaka Narita
Honoraria - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Otsuka
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; EPS Associates Co., Ltd.; GlaxoSmithKline; Meiji Seika Kaisha; MSD; Ono Pharmaceutical; Otsuka; SBI Pharmaceuticals; Stella pharma; Toshiba
 
Yoshihiro Muragaki
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Hitachi Chemical; MSD; Novartis; Otsuka
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi Chemical (Inst); MSD (Inst); Otsuka (Inst)
 
Takashi Maruyama
No Relationships to Disclose
 
Naoki Kagawa
Honoraria - Chugai Pharma
Consulting or Advisory Role - Gunze
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Gunze; Otsuka
 
Katsunori Asai
No Relationships to Disclose
 
Junichiro Kuroda
No Relationships to Disclose
 
Kazuhiko Kurozumi
No Relationships to Disclose
 
Motoo Nagane
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Infront; MSD; Nippon Kayaku; Novocure; Ono Pharmaceutical; Springer
Consulting or Advisory Role - Abbvie; Chugai Pharma; Dainippon Sumitomo Pharma; Novocure
Research Funding - Abbvie; Astellas Pharma (Inst); Chugai Pharma; CSL Behring (Inst); Daiichi Sankyo; Eisai; HOYA Techonosurgical (Inst); MSD; Nihonkayaku (Inst); Ono Pharmaceutical; Otsuka (Inst); Pfizer (Inst); Saney Seiko (Inst); Sanofi (Inst); Sanofi (Inst); Shionogi (Inst); Takeda (Inst); Toray Industries; Tsumura & Co. (Inst); Tsumura & Co. (Inst)
Patents, Royalties, Other Intellectual Property - Toray Industries
Travel, Accommodations, Expenses - Abbvie; Chugai Pharma; Daiichi Sankyo; Eisai; MSD K.K; Ono Pharmaceutical
 
Masahid Matsuda
No Relationships to Disclose
 
Keisuke Ueki
No Relationships to Disclose
 
Christopher Joseph Ocampo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ikiru Matsumoto
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Reiko Odagawa
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Yasuko Nishimura
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Kazuhiko Mishima
Speakers' Bureau - Chugai Pharma; Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Medical U and A, Inc; MSD; Nihon Medi-Physics; Ono Pharmaceutical; Otsuka; Teijin Pharma